Skip to main content

Drug Interactions between Caprelsa and Lytgobi

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

No interactions were found between Caprelsa and Lytgobi. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Caprelsa

A total of 323 drugs are known to interact with Caprelsa.

Lytgobi

A total of 175 drugs are known to interact with Lytgobi.

Drug and food interactions

Major

futibatinib food

Applies to: Lytgobi (futibatinib)

Grapefruit juice can increase the blood levels of futibatinib. This may increase side effects including dry or inflamed eyes, inflamed cornea, increased tears, disorder of the retina, high phosphate levels in your blood, redness, swelling, peeling or tenderness, mainly on the hands or feet, nails separating from the bed or poor formation of the nail, urinary tract infection, constipation, diarrhea, dry mouth, abdominal pain, fatigue, muscle and joint pain, decreased levels of blood cells (white blood cells, red blood cells, and platelets), and changes in liver function blood tests. You should avoid the consumption of grapefruit and grapefruit juice during treatment with futibatinib. Be sure to take the medication at approximately the same time every day to maintain consistent blood levels and effects. Talk to your doctor or pharmacist if you have questions on how to take this or other medications you are prescribed. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Therapeutic duplication warnings

Therapeutic duplication is the use of more than one medicine from the same drug category or therapeutic class to treat the same condition. This can be intentional in cases where drugs with similar actions are used together for demonstrated therapeutic benefit. It can also be unintentional in cases where a patient has been treated by more than one doctor, or had prescriptions filled at more than one pharmacy, and can have potentially adverse consequences.

Duplication

Multikinase inhibitors

Therapeutic duplication

The recommended maximum number of medicines in the 'multikinase inhibitors' category to be taken concurrently is usually one. Your list includes two medicines belonging to the 'multikinase inhibitors' category:

  • Caprelsa (vandetanib)
  • Lytgobi (futibatinib)

Note: In certain circumstances, the benefits of taking this combination of drugs may outweigh any risks. Always consult your healthcare provider before making changes to your medications or dosage.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer